^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

minocycline

Associations
Company:
Generic mfg.
Drug class:
Immunomodulator, Protein synthesis inhibitor, IL-1α inhibitor, IL-6 modulator
Related drugs:
Associations
16d
Study on the Clinical Efficacy of Combined Therapy with Minocycline Hydrochloride Ointment and Tinidazole for Chronic Periodontitis: Retrospective Study. (PubMed, J Inflamm Res)
Compared with minocycline hydrochloride alone, the addition of tinidazole further improved patients' periodontal health, reduced the inflammatory response and MMP-9, SIgA levels, and did not increase the risk of adverse reactions. This suggests good drug safety and clinical promotion value.
Retrospective data • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • MMP9 (Matrix metallopeptidase 9) • IL1B (Interleukin 1, beta) • CRP (C-reactive protein)
|
minocycline
17d
Enrollment closed • Enrollment change • Adverse events
|
EGFR (Epidermal growth factor receptor)
|
EGFR L858R • EGFR exon 19 deletion
|
Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • amivantamab SC (Ami-LC) • minocycline
22d
New trial
|
minocycline
22d
New P4 trial
|
minocycline
22d
New P4 trial
|
minocycline
22d
A large-scale population study on the eradication effect of Helicobacter pylori (ChiCTR2500097338)
P=N/A, N=5000, Not yet recruiting, Fujian Medical University; Fujian Medical University
New trial
|
minocycline
22d
New trial
|
minocycline
22d
A preliminary study of a novel dual regimen in patients first treated for Helicobacter pylori infection (ChiCTR2500096313)
P=N/A, N=140, Not yet recruiting, Peking University Third Hospital; Peking University Third Hospital
New trial
|
minocycline
27d
Enrollment change
|
EGFR (Epidermal growth factor receptor)
|
EGFR L858R • EGFR exon 19 deletion
|
Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • amivantamab SC (Ami-LC) • minocycline
1m
Exploring the Effectiveness and Potential Pharmacological Mechanism of Minocycline for Spinal Cord Injury through Meta-Analysis and Network Pharmacology. (PubMed, Curr Neuropharmacol)
Finally, molecular docking results showed B-cell CLL/lymphoma 2 (BCL2-6), CTNNB1, HSP90AA1, plasminogen activator urokinase (PLAU), and α protein kinase C alpha (PRCAKA) bound to minocycline better. This article concluded that minocycline was effective in treating SCI by improving neurological recovery and inhibiting oxidative stress, apoptosis, and inflammation.
Clinical • Retrospective data • Journal
|
EGFR (Epidermal growth factor receptor) • BCL2 (B-cell CLL/lymphoma 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CTNNA1 (Catenin Alpha 1) • PRKCA (Protein Kinase C Alpha) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
|
minocycline
1m
Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis (clinicaltrials.gov)
P2, N=40, Recruiting, Xijing Hospital | Trial completion date: Dec 2028 --> Apr 2025 | Trial primary completion date: May 2028 --> Jan 2025
Trial completion date • Trial primary completion date
|
minocycline
2ms
Enrollment open • Adverse events
|
EGFR (Epidermal growth factor receptor)
|
EGFR L858R • EGFR exon 19 deletion
|
Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • amivantamab SC (Ami-LC) • minocycline
2ms
Enrollment closed • Adverse events
|
EGFR (Epidermal growth factor receptor)
|
EGFR L858R • EGFR exon 19 deletion
|
Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • amivantamab SC (Ami-LC) • minocycline
2ms
Microglia-Mediated Synaptic Dysfunction Contributes to Chemotherapy-Related Cognitive Impairment. (PubMed, J Neurochem)
Adult male mice were treated with the chemotherapeutic drugs 5-fluorouracil and leucovorin (5-Fu/LV, intraperitoneal injection, I.P.) on Days 1, 8, and 15 at a dosage of 50 mg/kg for 5-Fu and 90 mg/kg for LV for 3 weeks...Furthermore, 5-Fu/LV treatment reduced the long-term potentiation (LTP) recorded in the hippocampal CA1 region in response to a theta burst stimulation of the CA3-CA1 pathway and decreased the evoked N-methyl-D-aspartic acid receptor (NMDAR)-excitatory postsynaptic currents (NMDAR-EPSCs) in CA1 neurons. Cotreatment with the microglial inhibitor minocycline (33 mg/kg, daily for 3 weeks) restored cognitive deficits and microglial ramification, decreased the number of CD68-positive microglia, and reversed the reductions in LTP and the amplitude of NMDAR-EPSCs in 5-Fu/LV-treated mice. Our data suggest that microglial dysfunction and related synaptic dysfunction contribute to 5-Fu/LV-induced cognitive impairment.
Journal
|
CD68 (CD68 Molecule)
|
5-fluorouracil • leucovorin calcium • CA3 • minocycline
2ms
Trial primary completion date • Adverse events
|
EGFR (Epidermal growth factor receptor)
|
EGFR L858R • EGFR exon 19 deletion
|
Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • amivantamab SC (Ami-LC) • minocycline
2ms
New P4 trial
|
minocycline
2ms
Myelination Trajectory and Microglial Dynamics Following Repeated Sevoflurane Exposure in Developing Brain. (PubMed, Glia)
The conditioned medium from sevoflurane-treated microglia inhibited the OPC proliferation and differentiation, while minocycline or PLX5622 alleviated sevoflurane-induced neuroinflammation and hypomyelination. Therefore, repeated sevoflurane exposure negatively affected OPC differentiation and myelination trajectory through hyperactivating microglia in developing brain, leading to motor and cognitive impairments, while microglial inhibition/depletion could protect against sevoflurane-induced damage on developing myelination.
Journal
|
PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
|
minocycline
3ms
Leprosy reactions: New knowledge on pathophysiology, diagnosis, treatment and prevention. (PubMed, Indian J Dermatol Venereol Leprol)
Therapies for ENL management, such as thalidomide, methotrexate, apremilast, minocycline and tumour necrosis factor-alpha inhibitors, hold potential. This review addresses recent advances in leprosy reaction pathogenesis and diagnostics, offering therapeutic insights and preventive strategies to mitigate their onset.
Review • Journal • IO biomarker
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • IL10 (Interleukin 10) • TLR9 (Toll Like Receptor 9) • IL21 (Interleukin 21)
|
methotrexate • thalidomide • minocycline
3ms
Depressive and Negative Symptoms in the Early and Established Stages of Schizophrenia: Integrating Structural Brain Alterations, Cognitive Performance, and Plasma Interleukin 6 Levels. (PubMed, Biol Psychiatry Glob Open Sci)
We evaluated whether higher plasma interleukin 6 (IL-6) levels would be associated with more severe negative or depressive symptoms in schizophrenia and explored illness stage utilizing early (BeneMin [Benefit of Minocycline on Negative Symptoms of Psychosis: Extent and Mechanism], n = 201, 72.8% male) and established (iRELATE [Immune Response & Social Cognition in Schizophrenia], n = 94, 67.3% male) schizophrenia cohorts...All analyses were adjusted for sex, age, and chlorpromazine equivalent dose...Our results indicate that higher plasma IL-6 levels may be differently associated with the severity of depressive and negative symptoms dependent on the illness stage. Future work identifying elevated levels of inflammation in larger samples may allow stratification and personalized intervention by subgroups who are at risk of poor outcomes.
Journal
|
IL6 (Interleukin 6)
|
chlorpromazine • minocycline
3ms
New trial
|
IL17C (Interleukin 17C)
|
minocycline
3ms
New P1 trial
|
hydroxychloroquine • minocycline
4ms
OSU-13165: Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer (clinicaltrials.gov)
P2, N=56, Completed, Ohio State University Comprehensive Cancer Center | Active, not recruiting --> Completed
Trial completion
|
minocycline
4ms
Enrollment open
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • IFNA1 (Interferon Alpha 1) • CRP (C-reactive protein)
|
minocycline
4ms
Minocycline ameliorates cognitive impairment in rats with trigeminal neuralgia by regulating microglial polarization. (PubMed, Int Immunopharmacol)
Moreover, it was found that the TLR4/MyD88/NF-κB pathway was involved in the shift of microglia from a pro-inflammatory (M1) to an anti-inflammatory (M2). In summary, minocycline likely mediated the process of microglia polarization partly via the TLR4/MyD88/NF-κB pathway, promoting neuronal survival and restoring synaptic plasticity, thereby improving TN-related cognitive impairment.
Preclinical • Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • TLR4 (Toll Like Receptor 4) • IL4 (Interleukin 4)
|
minocycline
4ms
Antihypertensive Mechanisms of Minocycline in Resistant Hypertension (clinicaltrials.gov)
P4, N=120, Recruiting, University of Florida | Not yet recruiting --> Recruiting
Enrollment open
|
minocycline
5ms
MINO-SCD: Minocycline in Neurocognitive Outcomes - Sickle Cell Disease (clinicaltrials.gov)
P1, N=30, Not yet recruiting, University of Cincinnati | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> May 2026
Trial completion date • Trial primary completion date
|
minocycline
5ms
Stony Brook Medicine Anti-Inflammatory Trial (clinicaltrials.gov)
P4, N=42, Not yet recruiting, Stony Brook University
New P4 trial
|
celecoxib oral • minocycline
5ms
Mino-PK: Pharmacokinetic Study of Minocycline in Patients With Pulmonary Nontuberculous Mycobacterial Disease (clinicaltrials.gov)
P2, N=15, Recruiting, Radboud University Medical Center | Trial completion date: Sep 2024 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
Trial completion date • Trial primary completion date • Nontuberculous mycobacteria
|
minocycline
5ms
New P1 trial
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • IFNA1 (Interferon Alpha 1) • CRP (C-reactive protein)
|
minocycline
5ms
PINK1-deficiency facilitates mitochondrial iron accumulation and colon tumorigenesis. (PubMed, Autophagy)
Clinically used drugs deferiprone and minocycline reduced mitochondrial iron and superoxide levels, resulting in decreased colon tumor cell growth in vitro and in vivo. Manipulating the mitochondrial iron uptake protein MCU (mitochondrial calcium uniporter) also affected cell and xenograft tumor growth. This study suggests that therapies aimed at reducing mitochondrial iron levels may effectively inhibit colon tumor growth, particularly in patients with low PINK1 expression.
Journal
|
PTEN (Phosphatase and tensin homolog) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3) • PINK1 (PTEN Induced Kinase 1)
|
minocycline
5ms
CXCL1-CXCR2 signaling mediates the activation of microglia in the nucleus tractus solitarii to promote pancreatic cancer-induced pain. (PubMed, Brain Behav Immun)
In mice with pancreatic cancer-induced pain, the microglia activation in the NTS was observed, characterized by increased cell density and decreased process number and length, while injection of microglia inhibitor minocycline in the NTS alleviated pancreatic cancer-induced pain...Blocking CXCL1-CXCR2 signaling by injection of CXCL1 neutralizing antibody or CXCR2 antagonist SB225002 in the NTS of mice with pancreatic cancer-induced pain alleviated abdominal hypersensitivity and hunching behavior, and also reversed the activation of neurons and microglia. Additionally, injection of recombinant CXCL1 in the NTS of sham-operated mice induced abdominal pain, and activated the neurons and microglia. In summary, our study highlights the critical role of NTS microglia activation mediated by CXCL1-CXCR2 signaling in pancreatic cancer-induced pain.
Journal
|
CXCR2 (Chemokine (C-X-C motif) receptor 2) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
|
SB225002 • minocycline
5ms
New P4 trial
|
minocycline
5ms
A multicenter, randomized, double-blind, placebo-controlled clinical study of bifidobacterium quadruple viable tablets assisted P-CAB quadruple therapy for refractory Helicobacter pylori infection (ChiCTR2400090233)
P4, N=574, Not yet recruiting, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University o
New P4 trial
|
minocycline
6ms
Impact of ciprofloxacin with autophagy on renal tubular injury. (PubMed, Medicine (Baltimore))
This indicates that ciprofloxacin enhances autophagy, increasing the amount of free Beclin-1 via phosphorylated Bcl-2, and inhibits caspase activity. Therefore, ciprofloxacin might protect against renal tubular injury through the activation of autophagy in the setting of acute kidney injury.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • BECN1 (Beclin 1)
|
minocycline
6ms
Enrollment change • Adverse events • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR L858R • EGFR exon 19 deletion
|
Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • minocycline
7ms
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response (clinicaltrials.gov)
P3, N=400, Recruiting, University of Nebraska | Trial primary completion date: Mar 2026 --> Mar 2027
Trial primary completion date
|
CRP (C-reactive protein)
|
Rituxan (rituximab) • hydroxychloroquine • tofacitinib • Kevzara (sarilumab) • leflunomide • minocycline
7ms
New P1 trial
|
minocycline
8ms
Central innate immunization induces tolerance against post-traumatic stress disorder-like behavior and neuroinflammatory responses in male mice. (PubMed, Brain Behav Immun)
Inhibition of microglia by pretreatment with minocycline or depletion of microglia by PLX3397 abolished the preventive effect of low-dose LPS pre-injection on mSPS-induced anxiety- and fear-like behavior and neuroinflammatory responses. These results suggest that pre-stimulation of microglia may prevent the development of PTSD-like behaviors by attenuating the development of neuroinflammatory responses. This could help to develop new strategies to prevent the damaging effects of harmful stress on the brain.
Preclinical • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
|
Turalio (pexidartinib) • minocycline